Medtronic touts improved patient survival in AdaptivCRT algorithm study

Medtronic (NYSE:MDT) today released results from a study of its AdaptivCRT algorithm, touting that the use of the algorithm increased patient survival. Results from the trial were presented last week at the Heart Rhythm Society’s annual scientific sessions in Boston, the Fridley, Minn.-based company said. The AdaptivCRT algorithm is designed to personalize cardiac resynchronization therapy and adjusts how implanted CRT devices pace the heart according to evaluations of the patient’s heart rhythm, Medtronic said. In the AdaptResponse prospective registry study, researchers explored the use of the AdaptivCRT Algorithm across 1,835 patients, and found that use of the algorithm was associated with a 31% relative reduction in all-cause mortality compared to standard CRT devices. “With AdaptivCRT, we are treating heart failure comprehensively, with technology designed to address the individual needs of each patient. This analysis shows yet another benefit of AdaptivCRT, and we look forward to results from the randomized, superiority AdaptResponse trial in the coming years,” Medtronic cardiac resynchronization therapy biz GM Dr. Kweli Thompson said in a press release. Medtronic said that prior studies of the algorithm have shown that it can also reduce atrial fibrillation, with data indicating a 46% reduction in episodes of AS lasting more than 48 hours compared to traditional CRT. “Heart failure patients typically have several other medical c...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Medtronic Source Type: news

Related Links:

AbstractBackgroundPermanent right ventricular pacing (RVP) results in cardiac dyssynchrony that may lead to heart failure and may be an indication for the use of cardiac resynchronization therapy (CRT). The study aimed to evaluate predictors of outcomes in patients with pacing ‐induced cardiomyopathy (PICM) if upgraded to CRT.Methods115 patients, 75.0 years old (IQR 67.0 –80.0), were upgraded to CRT due to the decline in left ventricle ejection fraction (LVEF) caused by the long‐term RVP. A retrospective analysis was performed using data from hospital and outpatient clinic records and survival data from the natio...
Source: Pacing and Clinical Electrophysiology : PACE - Category: Cardiology Authors: Tags: DEVICES Source Type: research
AbstractBackgroundCardiac resynchronization therapy (CRT) is indicated in patients with medically refractory heart failure and wide QRS duration. While much is known about predictors of left ventricular (LV) remodeling after CRT implantation and short ‐term mortality, limited data exist on long‐term outcomes after CRT placement.MethodsWe retrospectively reviewed all patients undergoing CRT implantation at our center between 2003 and 2008 and examined mortality using institutional electronic records, social security death index, and online obituary search. We included only patients with preimplant echoes with LV ejectio...
Source: Journal of Cardiovascular Electrophysiology - Category: Cardiology Authors: Tags: DEVICE THERAPY Source Type: research
ConclusionA 24 ‐hour increase in AF burden is associated with a more than two‐fold increased risk of HF events over the subsequent week while the long‐term AF burden is not significantly associated with HF events.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - Category: Cardiology Authors: Tags: ORIGINAL ‐ ELECTROPHYSIOLOGY Source Type: research
Conclusion In our experience, patients with RV dysfunction less likely benefited from CRT. RV assessment, studied with CMR, appears to be a good predictor of the response to biventricular stimulation.
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Research articles: Heart failure Source Type: research
CONCLUSIONA large proportion of patients are still alive 10 years after CRT implantation. Variables at the time of CRT implant can help provide prognostic information to patients and electrophysiologists to determine the long ‐term benefit and survival of patients after CRT implantation.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - Category: Cardiology Authors: Tags: DEVICE THERAPY Source Type: research
Abbott Laboratories continues to extend its list of milestones in the cardiovascular space. The Abbott Park, IL-based company has now won Breakthrough Device Designation from FDA for the in-development Fully Implantable Left Ventricular Assist System (FILVAS). FILVAS builds on the HeartMate 3 Left Ventricular Assist Device (LVAD). The technology was inherited by St. Jude Medical when it was acquired by Abbott. St. Jude inherited Heartmate 3 after it acquiredThoratec for $3.4 billion. Kevin Bourque, Divisional Vice President of Research &Development for Abbott’s Mechanical Circulatory Support portfol...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Regulatory and Compliance Source Type: news
Michel Mirowski and his colleagues gave the field of implantable cardioverter-defibrillators (ICDs) a pretty good start, but what's more impressive is how far the technology has advanced since that first human ICD implant in February 1980. In the past 40 years we've seen ICDs become dramatically smaller, longer lasting, more capable, more personalized, subcutaneous (non-transvenous), and even MRI-firendly. And that's not to mention the advanced data connectivity and monitoring capabilities that the latest technologies offer. So without further ado, let's take a look at the current ICD landscape and the companie...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news
Medtronic has announced that its Cobalt and Crome implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators (CRT-D) won EU CE Mark clearance, allowing their introduction to the continent. The devices featu...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Cardiology Source Type: blogs
Authors: Abe S, Yoshihisa A, Ichijo Y, Sato Y, Kanno Y, Takiguchi M, Yokokawa T, Misaka T, Sato T, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Takeishi Y Abstract It has been recently recognized that recovery of left ventricular ejection fraction (EF), termed "recovered EF", occurs in a proportion of heart failure patients with reduced EF (HFrEF), and is associated with better prognosis. However, the clinical characteristics of "recovered EF" have not been fully examined.Consecutive 567 patients hospitalized due to HFrEF (EF
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
ConclusionThis analysis from the European CRT Survey II overall shows good guideline adherence, high implantation success and a low rate of complications in daily practice. There are some regional differences in baseline characteristics, CRT indication, and procedural aspects. The use of remote monitoring in Germany lags behind other European countries.Graphic abstract
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Cardiac Resynchronization Therapy | Cardiology | Cardiovascular | Clinical Trials | Heart | Heart Failure | Hospitals | Study